non-small cell lung cancer
Conditions
Interventions
Group A:Thoracic radical radiotherapy+Anlotinib
Sponsors
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70, gender unlimited; 2. Histologically or cytologically proven stage III unresectable non-small cell lung cancer with non-squamous tissue or mixed tissue with less than 50% squamous cells; 3. EGOG =80 points, have received systemic chemotherapy for >=4 weeks; 4. Egog >=2 points, only simple radical radiotherapy can be performed; Refuse concurrent chemotherapy or cannot tolerate concurrent chemotherapy due to other comorbidies; 5. No cavity or primary tumor within 1 cm around the main blood vessel; The patient had no hemoptysis symptoms; 6. Life expectancy >6 months; 7. Satisfy the following laboratory diagnostic indicators: (1)Hemoglobin >=90 g/L, white blood cell >=3.0x10^9/L, Neutrophils >=1.5x10^9/L, platelets >=75x10^9/L; (2)Creatinine <=1.5 times the upper normal limit (UNL), total bilirubin (TBIL) <=1.5 times UNL; (3)Alanine aminotransferase (ALT), aspartate aminotransferase (AST) <= 2.5 times UNL, Alkaline phosphatase (ALP), glutamyl transpeptidase (GGT) <=2.5 times UNL; (4)Urinary protein was negative. 8. Women of childbearing age agree to use contraception during treatment; 9. Have the conditions for follow-up; 10. Signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. A history of other site malignancies being treated, excluding curable non-black pigmented skin cancer and cervical carcinoma in situ; If previous malignant tumors received radical treatment and had no recurrence for 5 years, they could be included in the group; 2. Previous chest radiotherapy; 3. Complicated with obvious hemoptysis; 4. Myocardial infarction, cerebrovascular accident, or uncontrollable and active pulmonary inflammation occurred within 3 months before enrollment; 5. Treatment regimens in current or other clinical trials participated in within 4 weeks prior to inclusion are different from those in this study; 6. Pregnant women; 7. Other nonconformities considered by the reviewers from the enrollment study to have good reason: if there are potential nonconformities with the clinical protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety;objective remission rate;Disease progression rate and survival; | — |
Countries
China
Contacts
Public ContactNan Bi
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Outcome results
None listed